 Invitae, a next-gen healthcarebiotech company, has seen its stock getting hammered due to strong worries about a looming bankruptcy due to reckless cash burn. However, in the last few quarters, the company has started to shift from growth-at-all-costs to focusing on reducing the cash burn, with a 100M annualized reduction in Q1 alone. 